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Background and purpose — Blood metal ion levels can be an indi-
cator for detecting implant failure in metal-on-metal (MoM) hip 
arthroplasties. Little is known about the effect of bilateral MoM 
implants on metal ion levels and patient-reported outcomes. We 
compared unilateral patients and bilateral patients with either an 
ASR hip resurfacing (HR) or an ASR XL total hip replacement 
(THR) and investigated whether cobalt or chromium was associ-
ated with a broad spectrum of patient outcomes.
Patients and methods — From a registry of 1,328 patients 
enrolled in a multicenter prospective follow-up of the ASR Hip 
System, which was recalled in 2010, we analyzed data from 659 
patients (311 HR, 348 THR) who met our inclusion criteria. 
Cobalt and chromium blood metal ion levels were measured and 
a 21-item patient-reported outcome measures (PROMs) question-
naire was used mean 6 years after index surgery.
Results — Using a minimal threshold of > 7 ppb, elevated chro-
mium ion levels were found to be associated with worse health-
related quality of life (HRQoL) (p < 0.05) and hip function (p < 
0.05) in women. These associations were not observed in men. 
Patients with a unilateral ASR HR had lower levels of cobalt ions 
than bilateral ASR HR patients (p < 0.001) but similar levels of 
chromium ions (p = 0.09). Unilateral ASR XL THR patients had 
lower chromium and cobalt ion levels (p < 0.005) than bilateral 
ASR XL THR patients. 
Interpretation — Chromium ion levels of > 7 ppb were associ-
ated with reduced functional outcomes in female MoM patients.
■
Since the late 1990s, the popularity of metal-on-metal (MoM) 
hip implants has risen due to the potential for low volumetric 
wear and high performance in young and active patients (Bozic 
et al. 2009). By 2010, however, the use of MoM declined over 
concerns of adverse local tissue reactions (ALTRs) (Porter 
et al. 2010). The Articular Surface Replacement (ASR) Hip 
System, comprised of the ASR hip resurfacing (HR) and the 
ASR XL total hip replacement (THR), was a MoM system 
implanted in over 90,000 patients worldwide prior to its recall 
in 2010 due to higher than expected 5-year revision rates 
(DePuy Orthopaedics, Warsaw, IN) (Cohen 2011, Bernthal 
et al. 2012). Recommended protocol for patients with MoM 
implants includes regular clinical follow-up with physician 
assessment, blood metal ion testing, plain radiographs, and 
soft-tissue imaging when necessary (MHRA 2012, Kwon 
et al. 2014). Metal ion levels may be useful as a method for 
detection of increased wear and poor hip function in MoM 
patients (Haddad et al. 2011, Van Der Straeten et al. 2013). 
Currently, guidelines for metal ion levels only apply to unilat-
eral MoM implants due to the confounding nature of interpret-
ing blood metal ion levels in patients with bilateral MoM hip 
arthroplasty (Kwon et al. 2014).
The connection between chromium or cobalt and ALTRs 
is not fully understood. There is neither an established metal 
ion “safe zone” nor a maximum threshold that can reliably 
predict implant failure (Langton et al. 2011, Hart et al. 2014). 
Little has been published on how cobalt and chromium metal 
ion levels differ between patients with unilateral and bilateral 
ASR hip systems. Although many studies have investigated 
the blood metal ion levels in MoM arthroplasty patients, they 
have been limited by several factors: use of a mixed cohort 
of different THR and/or HR systems, focusing solely on uni-
lateral implants, or grouping unilateral and bilateral patients 
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together (Maezawa et al. 2010, Hug et al. 2013, Jantzen et 
al. 2013, Penny et al. 2013, Savarino et al. 2013, Hart et al. 
2014, Bisseling et al. 2015). Furthermore, the few studies that 
have assessed the effect of bilateral implants on blood metal 
ion levels used relatively small patient cohorts or a variety of 
HR prostheses (Pelt et al. 2011, Van Der Straeten et al. 2013).
The fi rst purpose of this prospective observational cohort 
study was to evaluate blood metal ion levels and patient-
reported outcome measures (PROMs) in patients with ASR 
HR or ASR XL THR. The second purpose was to assess the 
effect of bilateral ASR HR or ASR XL THR on blood metal 
ion levels and PROMs. Finally, we determined whether previ-
ously established blood metal ion threshold levels were asso-
ciated with different PROMs.
Patients and methods 
The study population consisted of 1,328 arthroplasty patients 
enrolled in a multicenter follow-up study of the ASR Hip 
System (DePuy Orthopaedics, Warsaw, IN). Enrollment of 
unrevised, primary ASR patients willing to participate in a 
6-year follow-up study took place from May 2012 through 
December 2014. Data abstractors reported anonymized medi-
cal record data and PROMs to Massachusetts General Hospi-
tal in Boston from 15 centers in 5 countries through a secure, 
web-based data entry and monitoring system. All the patients 
enrolled signed the informed consent document and met the 
following inclusion criteria: any unrevised patient (1) with on-
label use of the ASR XL THR or ASR HR system; (2) willing 
to return for annual follow-up for 5 years; and (3) able to com-
plete a 21-item PROMs questionnaire. The following exclu-
sion criteria were used: any patient (1) who received the ASR 
XL THR implant as a result of a hip resurfacing conversion or 
a revision THR; or (2) who had diffi culty in comprehending 
the informed consent form for any reason.
For our analysis, we included all patients with complete data 
at enrollment using the following criteria: (1) available femo-
ral and acetabular component catalog numbers; (2) valid AP 
pelvis X-ray to measure cup inclination angle; (3) completed 
PROMs including the Harris hip score (HHS) (Harris 1969), 
EQ-5D (EuroQolGroup 1990), UCLA activity score (Amstutz 
et al. 1984), and VAS pain score (0–10) (Hawker et al. 2011); 
(4) whole blood cobalt and chromium ion levels. We excluded 
patients from our analysis if they had: (1) a non-ASR con-
tralateral implant system; or (2) an ASR HR on 1 side and a 
contralateral ASR XL THR. 
The metal ion concentrations and PROMs were obtained at 
a mean of 6 (2–11) years from index surgery. Whole blood 
samples were assessed by certifi ed laboratories using stan-
dardized collection methods. The study cohort was divided 
into 2 groups, ASR HR and ASR XL THR. Each of these 
groups was further divided into 2 subgroups: patients with 
unilateral implants and those with bilateral implants (Figure 
1). We used 7 ppb and 10 ppb as the metal ion threshold levels 
described for high-risk patients based on recent MoM follow-
up algorithms (MHRA 2012, Kwon et al. 2014).
Demographics of the patient population
The inclusion criteria gave 659 patients (311 ASR HR, 348 
ASR XL THR). The mean age at index surgery was 59 (18–
95) years and 246 patients (37%) were female (Table 1). 
Statistics
The study questions were analyzed as follows. Differences 
in blood metal ion levels and PROMs between unilateral and 
bilateral ASR HR or ASR XL THR patients were assessed 
using the Mann-Whitney U-test for variables that did not 
follow a normal distribution and Student’s t-test for normally 
distributed data. The Shapiro-Wilk test was used to determine 
the normality of each variable and Levene’s test was used to 
ensure that the assumption of equal variances was met. The 





Excluded (n = 669):
– missing required data, 504
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        missing metal ion data, 8
        missing inclination angle measurements, 322
        missing femoral head size, 143












 a unilateral or bilateral
ASR HR or ASR XL THR
n = 1,328
Table 1. Demographic and surgery-related characteristics of the 
659 patients who received the MoM ASR Hip System
       
  ASR HR ASR XL THR
 n = 311 n = 348
Female, n (%)  92 (30) 153 (44)
Age at index surgery a  55 (18–80)   63 (24–95)
Years from index surgery to follow-up a 6.4 (2.8–10.1)  5.8 (2.4–8.8)
Diagnosis, n (%)    
  Idiopathic OA  276 (89) 302 (87)
  Secondary OA    14 (4.5)   21 (6.0)
  Unspecifi ed OA    20 (6.4)   24 (6.9)
  Rheumatoid arthritis      1 (0.3)     1 (0.3)
Femoral head size (IQR), mm b   51 (49–55)   49 (46–51)
Cup inclination angle (IQR), degrees b   45 (41–49)   43 (39–48)
MARS MRI available, n (%) 116 (37) 131 (38)
a Mean (range)
b Median (interquartile range).
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time from surgery, bilateral status, femoral head size, and 
cup inclination angle (< 55° or ≥ 55°) as exposure variables 
(Brodner et al. 2004, De Haan et al. 2008). Then, in an effort 
to determine which covariates were associated with various 
PROMs, we separately assessed EQ-5D index, HHS, VAS 
pain score, and UCLA activity score as outcome variables. 
The same set of exposure variables was used for all of these 
analyses and included age, sex, bilateral status, and chromium 
and cobalt with ≥ 7 ppb and ≥ 10 ppb binary thresholds. 
In order to assess possible non-linearity of age, we set up 4 
competing models: a linear model, a model with 1 knot spline, 
one with 2 knots, and one with 3 knots. The fi t of the models 
was then compared with the help of information criteria. Our 
data did not indicate a non-linear relationship between age and 
PROMs, so age was used as a linear term in our analyses.
The p-values, standardized coeffi cient (expected change in 
outcome that accompanies 1 unit change in exposure), and 
95% confi dence intervals (CIs) were calculated for all linear 
regression analyses. Any p-value < 0.05 was considered sig-
nifi cant. Statistical analyses were performed using SPSS ver-
sion 19 and R version 3.0.2 (Team 2015).
Ethics and registration
Informed consent was obtained from all patients and the study 
was approved by the Institutional Review Board or Ethics 
Committee at all participating centers and Massachusetts 
General Hospital. The study is registered at ClinicalTrials.gov 
(registration number: NCT01611233).
Results 
Patient-reported outcome measures (PROMs)
Patients with a unilateral ASR XL THR reported lower HHS, 
EQ-5D index, and UCLA scores than unilateral ASR HR 
patients (p < 0.05) (Table 2). Patients with bilateral ASR XL 
THR reported lower UCLA activity scores than patients with 
bilateral ASR HR (p < 0.01) (Table 2). Patients with bilateral 
ASR XL THR had lower HHS and UCLA activity scores than 
patients with unilateral ASR XL THR (p < 0.05) (Table 2).
Linear regression analyses of PROMs using thresh-
olds of 7 ppb for chromium and cobalt
In ASR XL patients, elevated chromium levels of ≥ 7 ppb in 
women were associated with lower hip function as measured 
by the HHS (p < 0.05). Bilateral hip replacements and chro-
mium levels ≥ 7 ppb in female patients were associated with 
worse health-related quality of life (HRQoL) as measured by 
the EQ-5D index (p < 0.05) (Figure 2). Female sex, increasing 
age, and chromium levels ≥ 7 ppb in women were associated 
with lower activity as measured by the UCLA activity score 
(p < 0.05) (Table 5, see Supplementary data). In ASR patients, 
no signifi cant associations were observed between cobalt or 
chromium levels ≥ 7 ppb and the HHS, UCLA, EQ5D, or VAS 
pain scores (Tables 7–14, see Supplementary data).
Linear regression analyses of PROMs using thresh-
olds of 10 ppb for chromium and cobalt
In ASR XL patients, female patients with chromium levels 
≥ 10 ppb had lower hip function as measured by the HHS 
(p < 0.05) (Figure 2). Female sex, increasing age, bilateral 
hip replacement, and chromium levels ≥ 10 ppb were associ-
ated with lower activity as measured by the UCLA activity 
score (p < 0.05) (Table 6, see Supplementary data). Bilateral 
hip replacements and chromium levels ≥ 10 ppb in female 
patients were associated with worse HRQoL as measured 
by the EQ-5D index (p < 0.05) (Figure 2). In ASR patients, 
no statistically signifi cant associations were found between 
cobalt or chromium levels ≥ 10 ppb and the HHS, UCLA, 
EQ5D, or VAS pain scores (Tables 7–14, see Supplementary 
data).
Differences in metal ion levels between ASR HR and 
ASR XL THR
Non-parametric univariate analysis showed that the blood 
metal ion levels of cobalt were higher in patients with uni-
lateral ASR XL THR than in patients with unilateral ASR (p 
< 0.001), although blood metal ion levels of chromium were 
similar (p = 0.1) (Table 2). The cobalt to chromium (Co/Cr) 
ratio was also higher in patients with unilateral ASR XL THR 
than in patients with unilateral ASR HR (p < 0.001). 
Table 2. Median (interquartile range) patient-reported outcome measures and blood metal 
ion levels in patients with an ASR HR or an ASR XL THR prosthesis
  ASR HR ASR XL THR
 Unilateral Bilateral Unilateral Bilateral
No. of patients 272 40 302 48
Cobalt ions, ppb 1.1 (0.6–2.2) 1.75 (1.1–3.0) 2.5 (1.2–6.7) 5.3 (2.5–13)
Chromium ions,  ppb 1.2 (0.7–2.0) 1.85 (1.1–2.5) 1.4 (0.9–2.6) 2.4 (1.3–4.1)
Ratio Co/Cr 1.0 (0.7–1.3) 1.1   (0.9–1.4) 1.7 (1.2–3.5) 2.1 (1.2–3.8)
Harris hip score  94 (87–97) 92    (74–97)  91 (81–97)  86 (77–94)
EQ-5D 1.0 (0.8–1.0) 0.95 (0.7–1.0) 0.8 (0.7–1.0) 0.8 (0.6–1.0)
UCLA 7    (6–8) 6      (6–8) 6    (5–8) 5    (4–7)
VAS pain 0.5 (0.0–1.5) 0.5   (0.0–3.0) 0.5 (0.0–1.5) 0.5 (0.0–2.0)
HHS was recorded for each hip. For bilat-
eral patients, we randomly selected a 
score from 1 hip for statistical analysis. 
We stratifi ed our cohort into 2 groups 
(ASR patients and ASR XL patients) and 
then conducted a series of linear regres-
sion analyses.  First, we performed anal-
yses to identify which covariates were 
associated with blood metal ion levels. 
For this purpose, 2 models were built that 
assessed cobalt and chromium separately 
as outcome variables with all available 
covariates that had previously been asso-
ciated with metal ion levels: age, gender, 
488 Acta Orthopaedica 2016; 87 (5): 485–491
The cobalt ion levels were higher in patients with bilateral 
ASR XL THR than in patients with bilateral ASR HR (p < 
0.001), although chromium ion levels were similar (p = 0.1) 
(Table 2). The Co/Cr ratio was higher for patients with bilat-
eral ASR XL THR than for those with bilateral ASR HR (p < 
0.001). 
Effect of bilateral ASR HR or ASR XL THR on blood 
metal ion levels
The cobalt ion levels in blood were higher in patients with 
bilateral ASR HR implants than in those with a unilateral ASR 
HR implant (p < 0.05), but chromium ion levels were similar 
between the groups (p = 0.09) (Table 2). The Co/Cr ratio was 
higher in patients with bilateral implants than in those with a 
unilateral implant (p < 0.05). 
Cobalt and chromium ion levels in patients with bilateral 
ASR XL THR implants were higher than in those with a uni-
lateral ASR XL THR implant (p < 0.005), although the groups 
had similar Co/Cr ratios (p = 0.2) (Table 2). 
Linear regression analysis of metal ions
In ASR XL patients, female sex and having bilateral hip 
chromium ion levels in ASR HR and ASR XL THR patients 
when comparing unilateral or bilateral groups. Furthermore, 
we found that patients with unilateral ASR HR had chromium 
ion levels that were comparable to those in patients with bilat-
eral ASR HR. However, bilateral ASR XL THR implants were 
associated with higher chromium ion levels than unilateral 
ASR XL THR implants. Although blood cobalt ion levels 
were statistically signifi cantly higher in patients with ASR XL 
THR than in those with ASR HR, and also higher in bilateral 
groups than in unilateral groups, cobalt ion levels ≥ 7 ppb or 
≥ 10 ppb were not found to be associated with any negative 
patient symptoms that were assessed. The lack of association 
between time from index surgery and blood metal ion levels 
may in part be explained by a previous study, which demon-
strated a lack of temporal variation in blood metal ion levels 
for patients with ASR HR  (Langton et al. 2013). Finally, our 
study highlights the importance of optimal acetabular cup ori-
entation in order to minimize edge loading and blood metal 
ion levels. 
Cobalt ion levels appeared to deviate more strongly between 
patients, whereas chromium ion levels showed greater consis-
tency in our study cohort. This observation may have been due 
Figure 2. The effect of ion levels on Harris hip score (HHS) and EQ-5D index adjusted for age, sex, 
and contralateral articulation. Any variable with a CI that did not include 0 represents a statistically 
signifi cant infl uence. Panels A and B correspond to HHS and EQ-5D outcomes with a chromium ion 
threshold of 7 ppb and panels C and D show the results of the same analysis using a threshold of 10 
ppb in ASR XL patients.
replacements were associated 
with higher chromium ion levels 
(p < 0.01). Both female sex and 
bilateral hip replacements were 
also associated with higher cobalt 
levels (p < 0.01) (Figure 3). 
In patients with the ASR hip 
resurfacing prosthesis, having 1 
or 2 (a potential case for patients 
with bilateral ASR) acetabular 
cup inclination angle ≥ 55° was 
associated with higher chromium 
metal ion levels (p < 0.01). No 
variables assessed were found to 
be associated with higher cobalt 
metal ion levels (Figure 4).
Discussion
In this multicenter study, we found 
an association between chro-
mium ion levels and a reduction 
in both hip function and HRQoL 
in female patients with unilateral 
or bilateral ASR XL THR. Inter-
estingly, this association was not 
observed in male patients. Cobalt 
ion levels, using both 7 and 10 
ppb thresholds, were not associ-
ated with hip function or HRQoL. 
In addition, we found similar 
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to smaller fl uctuations in chromium ion levels in whole blood 
caused by its higher affi nity for proteins such as albumin and 
transferrin, to which it can bind (Newton et al. 2012). Thus, 
chromium has lower renal excretion than cobalt, which has a 
high renal clearance (Daniel et al. 2010). High chromium ion 
levels in blood may be a more consistent indicator of a poorly 
functioning MoM prosthesis, which would explain its strong 
association with poor hip function and health-related QoL in 
our study. Although we found no association between health 
outcomes and blood cobalt ion levels, cobalt levels > 4.5 ppb 
have been identifi ed as being highly sensitive and specifi c for 
abnormal wear in MoM hip arthroplasty, and cobalt blood ion 
levels as low as 2 ppb may be considered abnormal (Sidagina-
male et al. 2013). 
In 2014, the American Association of Hip and Knee Sur-
geons, the American Academy of Orthopaedic Surgeons, and 
the US Hip Society published a consensus statement that out-
lined criteria for stratifying MoM patients into groups with 
low, medium, and high risk of failure (Kwon et al. 2014). The 
As a multicenter registry study, we could not evaluate whether 
patients had additional sources of Cr or Co such as occupa-
tional exposure, spinal hardware, or metal dental implants. As 
we did not have blood metal ion data from patients with staged 
procedures before and after arthroplasty of the second hip, we 
were unable to compare the effects of staged and simultaneous 
arthroplasty procedures on blood metal ion levels over time. 
Some ASR patients may have been revised before the study; 
thus, patients with early failures may have been excluded, 
giving selection bias. The main focus of this study, however, 
was on understanding the relationship between PROMs and 
ions in patients currently undergoing follow-up. Furthermore, 
because not all of the patients in our study cohort underwent 
a metal artifact reduction sequence (MARS) MRI, we were 
unable to correlate differences in metal ion levels to sever-
ity of ALTRs. In addition, without preoperative PROMs, we 
could not assess hip function, activity, hip pain, and HRQoL 
before the index hip arthroplasty, and thus cannot eliminate 
the possibility of selection bias contributing to some of the 
Figure 3. The effect of patient- and implant-related characteristics on the chromium and cobalt levels mea-
sured in ASR XL patients. Any variable with a CI that did not include 0 represents a statistically signifi cant 
infl uence.
Figure 4. The effect of patient- and implant-related characteristics on the chromium and cobalt levels mea-
sured in ASR hip resurfacing patients. Any variable with a CI that did not include 0 represents a statistically 
signifi cant infl uence.
algorithm proposed a 10 ppb 
threshold for identifi cation of 
patients with a high risk of fail-
ure. However, that recommen-
dation acknowledged that metal 
ion levels were confounded by 
having more than one cobalt 
and chromium implant, and that 
lack of evidence was a limita-
tion for assessment of the risk 
of metal ion levels in bilateral 
patients. Our fi ndings support a 
7 ppb threshold for blood chro-
mium ions for high-risk female 
patients in both unilateral MoM 
and bilateral MoM THR. Our 
results partially support a pre-
vious study which found that 
bilateral MoM HR patients have 
elevated blood metal ion levels 
(Van Der Straeten et al. 2013). 
However, we found that bilat-
eral MoM HR patients only had 
elevated blood cobalt ion levels. 
The HR cohort did not have 
statistically signifi cantly higher 
blood levels of chromium ions 
in bilateral patients. This differ-
ence may have been due to the 
inclusion of multiple HR sys-
tems by Van Der Straeten et al., 
as compared to our concentrat-
ing on the ASR HR in this study. 
We acknowledge that the pres-
ent study had some limitations. 
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associations that were observed. Height and weight were not 
collected on all patients, so we were unable to assess asso-
ciations between BMI and metal ion levels and PROMs. It is 
possible that an overweight patient would have worse HRQoL 
and higher chromium levels due to implant load. Lastly, we 
tried to analyze the relationship between current established 
metal ion thresholds and functional outcomes. Future efforts 
should be directed at establishing new thresholds.  
The study had a number of strengths. First, we focused on a 
single hip replacement system and compared the HR and THR 
variants. The multicenter and multinational nature of the study 
prevented bias that might be introduced from any individual 
surgeon’s experience. Strict inclusion criteria enabled robust 
statistical analysis on a broad set of data. The study made use 
of several PROMs to assess a diverse set of patient symptoms. 
Finally, this was the fi rst multicenter study to analyze a large 
cohort of ASR patients that differentiated HR from THR and 
unilateral from bilateral. 
In summary, we found that time from index surgery and 
patient age were not associated with high blood metal ion 
levels, which highlights the necessity to have continuous 
annual follow-up of MoM patients. Blood metal ion test-
ing should be evaluated as part of frequent and comprehen-
sive follow-up that includes a physical examination, plain 
radiographs, and soft-tissue imaging, if available. Regarding 
assessment of blood metal ion levels in female patients with 
MoM hip replacement, chromium ion levels ≥ 7 ppb appear to 
be associated with reduced functional outcomes in both unilat-
eral and bilateral patients.
Supplementary data
Tables 4–14 and Appendix are available on the website of Acta 
Orthopaedica (www.actaorthop.org), identifi cation number 
8884.
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